RxDoctor Payments Data

Padraic McCahill, MD

Urology · North Easton, MANPI 1730186693

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,201 of the $12,261 with a category attached, or 75.0%. It is spread thinly across 55 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,605, 4.7 times the $990 reported in 2019.

$12,261in general payments, 2019–2025

Across 408 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gyrus ACMI, Inc.$3K
  • Astellas Pharma US Inc$1K
  • Teleflex LLC$636
  • Antares Pharma, Inc.$507
  • Endo Pharmaceuticals Inc.$456
  • Johnson & Johnson$438
  • plus $6K from 49 others

What the payments were for

  • Consulting fees$2,68022%
  • Food & beverage$9,20175%
  • Education$3803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,261 in reported general payments places this provider in the 85th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$560,962
Medicare patients
1,045
Services billed
14,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron202$181,614
MyrbetriqMirabegron161$125,275
Tamsulosin Hcl815$14,829
Mirabegron ErMirabegron25$14,073
Finasteride754$12,043
Oxybutynin Chloride ErOxybutynin Chloride274$8,211
Testosterone47$7,125
Tolterodine Tartrate ErTolterodine Tartrate40$7,030
Potassium Citrate ErPotassium Citrate26$2,164
Estradiol40$1,981
NitrofurantoinNitrofurantoin Macrocrystal62$1,885
Alfuzosin Hcl ErAlfuzosin Hcl78$1,502
Testosterone Cypionate41$1,292
Solifenacin Succinate21$811
Cephalexin95$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$393$181,614202 claims
Astellas Pharma US IncMyrbetriq$1,371$125,275161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 327 urology providers in Massachusetts.

Other urology in North Easton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →